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Summary 
The impact of DNMT3A mutations in acute myeloid leukemia (AML) has been 
further emphasized by the recent progress in whole genome sequencing and over 20% 
of cytogenetically normal AML patients have somatic DNMT3A mutations with R882 
being a hot spot of mutation. The precise molecular mechanisms of mutated DNMT3A 
in leukemogenesis are largely unknown, even though it is known that Dnmt3a controls 
the epigenetic silencing of hematopoietic stem cell (HSC) regulatory genes through 
loss-of-function study. Here I show that, in murine transplantation experiments, 
recipients transplanted with DNMT3A mutant-transduced cells exhibit HSC 
accumulation. Differentiation-associated genes such as PU.1 are down-regulated 
without accompanying changes in methylation status of their promoter-associated CpG 
islands in DNMT3A mutant-transduced stem/progenitor cells, indicative of DNA 
methylation-independent mechanism. DNMT3A R882 mutant also promotes 
monoblastic transformation of murine bone marrow cells in vitro in combination with 
HOXA9 and contributes to insensitivity to ATRA-induced differentiation in AML cells. 
Molecularly, DNMT3A R882 mutant interacts with polycomb repressive complex 1 
 3 
 
(PRC1), leading to transcriptional silencing of PU.1. Suppression of the PRC1 complex 
impairs aberrant HSC accumulation, monoblastic transformation, and ATRA 
insensitivity by DNMT3A R882 mutation. Taken together, my results highlight the 
functional role of DNMT3A mutation, forming the basis for leukemia development. 
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Introduction 
Given that acute myeloid leukemia (AML) is a molecularly heterogeneous group 
of malignancies, each AML subtype is diagnosed based on multiple laboratory tests 
including cytogenetics and FISH. The classical taxonomy French-American-British 
(FAB) classification has contributed greatly to AML diagnosis mainly by morphology 
of leukemia cells. However, on the arrival of next generation sequencing, the genetic 
landscape of AML is going to be totally unveiled, leading to the need for the refined 
categorization of AML based on multiple profiles. For instance, among cytogenetically 
normal AML (CN-AML), NPM1-mutated AML or CEBP-mutated AML compose an 
original disease entity, which is reflected on the 2008 revision of the World Health 
Organization classification, in which karyotype abnormalities, morphology, and some 
frequent genetic features are key determinants
1
. The recent detailed mutational analyses 
have revealed several gene mutations in CN-AML, including DNMT3A, TET2, IDH1/2, 
and ASXL1
2-5
. Especially in these mutations, somatic mutations of DNMT3A, a 
member of DNA methyltransferases, occur in about 20% of AML, are mostly 
heterozygous and more frequently associated with CN-AML
6-8
. The characteristics of 
DNMT3A-mutated AML are the recurrence (30-35%) and the poor overall survival
7-10
. 
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DNMT3A mutations closely associate with NPM1, FLT3 and IDH1 mutations and 
frequently found in FAB M4/M5 myelomonocytic/monocytic AML
7,8,11
. Molecularly, 
DNA methyltransferases catalyze the transfer of a methyl group to the cytosine of CpG 
dinucleotides and, in particular, DNMT3A and DNMT3B are the main enzymes 
involved in de novo methylation, and their deficiency deprives embryonic stem cells 
(ESCs) of differentiation potential
12
. R882 is the hot spot to be mutated in AML, where 
R882H is the most prevalent, accounting for about 70-80% cases and R882C is the 
second most. It has recently reported that DNMT3A mutations caused loss of 
tetramerization capacity in vitro which led to defective methylase activity
6,8,13
. Although 
the most recent landmark analysis has revealed that DNMT3A-mutated AML samples 
have an apparent DNA hypo-methylation signature, there are no distinct gene 
expression profiles regarding DNMT3A mutations
11
. In conditional Dnmt3a-knockout 
mice studies, Dnmt3a-deleted hematopoietic stem cells (HSCs) have reduced 
differentiation potential leading to marked expansion of HSCs in vivo and up-regulation 
of self-renewal genes, which implied a critical role of Dnmt3a wild-type (WT) in 
silencing self-renewal of HSCs and in allowing for hematopoietic differentiation
14,15
. 
Although Dnmt3a loss causes both hypo- and hyper-methylation of HSCs in mice, some 
of HSC-associated genes such as Runx1 and Gata3 have hypo-methylated regions with 
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accompanying up-regulation of these genes, consistent with the classic regulatory 
model
14
.  
Polycomb-group proteins (PcG), global epigenetic transcriptional repressors, play 
crucial roles in many biological processes, including stem cell self-renewal, 
differentiation, and cancer development
16
. PcG proteins reside in two major complexes, 
polycomb repressive complex 1 (PRC1) and PRC2. PRC2 complex catalyzes lysine 27 
tri-methylation on histone H3 (H3K27me3), initiating gene suppression
17,18
. One 
currently and widely accepted hierarchical model is that CBX proteins in PRC1 
complex recognize H3K27me3 and bind to these loci, followed by recruitment of PRC1 
complex for the maintenance of gene silencing via chromatin compaction and 
placement of a repressive mark, histone H2AK119 ubiquitination
19,20
. In hematological 
malignancy development, as previously reported, the recruitment of PRC2 complex by 
PML/RAR fusion protein to retinoic acid (RA)-responsive genes is a critical step in 
the development of acute promyelocytic leukemia (APL)
21
, and PLZF/RAR fusion 
protein which exhibits more severe phenotype of APL interacts with not only PRC2 
complex but also PRC1 complex, accounting for non-response to all-trans RA 
treatment
22
. More recently, several groups have elucidated that Ezh2, a component of 
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PRC2 complex, is required for maintenance of MLL-AF9-mediated mouse leukemia 
model
23,24
. 
DNMT3A is well known to interact with several histone modifiers including PcG 
proteins to suppress their target gene expression
25-29
. The functional cooperation 
between DNA methyltranferase and PcG proteins is considered to be responsible for 
cancer development
30,31
. Indeed, 50% of genes frequently hyper-methylated in colon or 
prostate cancer are marked by H3K27me3 for de novo DNA methylation, consistent 
with the fact that EZH2 directly interacts with DNMT1, DNMT3A, and DNMT3B
25,32
. 
Similarly, CBX proteins and BMI1, components of PRC1 complex, also interacts with 
DNA metyltransferases and DNMT-associated protein DMAP1, respectively
26,33
. 
In spite of the recent progress listed above in DNMT3A studies, the mechanism 
through which DNMT3A mutations contribute to AML remains elusive. To clarify the 
function of DNMT3A mutation in leukemogenesis, I describe the characterization of 
exogenous DNMT3A R882 mutants in the hematopoietic compartment, elucidating that 
DNMT3A R882 mutant exhibits differentiation block of HSCs and promotes 
monoblastic transformation, in collaboration with HOXA9. Furthermore, I show that the 
enhanced interaction between DNMT3A R882 mutants and PRC1 complex leads to 
aberrant recruitment of PRC1 complex to regulatory regions of hematopoietic 
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differentiation-associated genes. These findings provide new insights into how 
DNMT3A mutation contributes to malignant transformation. 
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Materials and Methods 
Plasmids 
Plasmids encoding proteins of human wild-type DNMT3A, Flag- and Myc-tagged 
DNMT3A and its mutants cDNA were cloned into the EcoR1/BamH1 site of 
pBleuscript II. R882H and R882C mutants were constructed from wild-type DNMT3A 
by means of a PCR method. To produce protein expressing retrovirus and lentivirus, I 
used the following plasmids: pGCDNsam-DNMT3A WT-, R882H-, and 
R882C-IRES-EGFP, pGCDNsam-DNMT3A WT-, R882H-, and R882C-IRES-Kusabira 
Orange (KuOr), CSII-EF-DNMT3A WT-, R882H-IRES2-Venus, 
CSIV-TRE-DNMT3A WT-, R882H-UbC-KT, pMYs-FLT3-ITD-IG, 
pMYs-HOXA9-IG, and pMYs-PU.1-IG. All of the PCR products were verified by 
DNA sequencing. The other plasmids used for transfection were as follows; 
pcDNA3-Flag-DNMT3A WT, R882H, and R882C, pcDNA3-Flag-BMI1, and 
pcDNA3-Flag-RING1B. 
 
Mice  
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Heterozygous Bmi1 knockout (KO) mice (Bmi1
+/-
 mice) were previously 
described
34
. Littermates were used as controls in all experiments. All animal 
experiments were approved by The University of Tokyo Ethics Committee for Animal 
Experiments and strictly adhered to the guidelines for animal experiments of The 
University of Tokyo. Bmi1
+/-
 mice were genotyped by PCR as follows: Genomic DNA 
was isolated from tail biopsies and subjected to PCR using the primers to detect WT and 
KO allele. The PCR samples were denatured at 94°C for 3 min, subjected to 30 cycles 
of amplification (94°C for 45 s, 65°C for 45 s, and 72°C for 45 s for WT allele, and 
94°C for 45 s, 58°C for 45 s, and 72°C for 45 s for KO allele), and followed by a final 
extension step at 72°C. PCR products were resolved by agarose gel electrophoresis. 
PCR primers are listed below: WT forward, AGCAGCAATGACTGTGATGC, and 
reverse, GTTGCTGGTTCCATTCATGG; KO forward, 
TCGTTATGTTTATCGGCACTTT, and reverse, AACATCGCCTCGCTCCAGTCAA. 
 
Cell Culture 
Human embryonic kidney (HEK) 293T cells were grown in D-MEM with 10% 
fetal calf serum (FCS) and 1% penicillin and streptomycin (PS) at 37°C in a 5% CO2 
incubator. HL-60, KG-1, and THP-1 cells were grown in RPMI1640 with 10% FCS and 
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1% PS at 37°C in a 5% CO2 incubator. OCI-AML3 cells were grown in -MEM with 
20% FCS and 1% PS at 37°C in a 5% CO2 incubator. KG-1 cells were provided by the 
RIKEN BRC through the National Bio-Resource Project of the NEXT, Japan. 
OCI-AML3 cells were provided by the German Resource Centre for Biological Material 
(DSMZ, Germany). For ATRA stimulation, cells were treated with 1 M ATRA for the 
indicated time. 
 
Retrovirus Production and Bone Marrow Transplantation (BMT) Assays 
To obtain retrovirus supernatants, Plat-E packaging cells were transiently 
transfected with retroviral constructs. 5-fluorouracil (5-FU)-primed or c-kit+-sorted 
C57/B6 mouse bone marrow (BM) cells were purified and incubated in -MEM with 
20% FCS, 1% PS, and cytokines (50 ng/mL mouse SCF and 25 ng/mL human TPO, 
IL-6, and FLT3) at 37°C in a 5% CO2 incubator for 24 h. Subsequently, cultured cells 
were infected with retrovirus in the presence of RetroNectin (Takara Bio Inc.). The 
infected cells were harvested 48 h after retrovirus infection, and vector-transduced cells 
were sorted and subjected to in vitro culture and in vivo transplantation assay. These 
cells were injected into lethally irradiated (9.5 Gy) recipient mice.  For experiments of 
assessing the repopulating capacity, 5-FU-primed mouse BM cells were transduced with 
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pGCDNsam-EGFP, pGCDNsam-DNMT3A WT-IRES-EGFP, pGCDNsam-DNMT3A 
R882H-IRES-EGFP, or pGCDNsam-DNMT3A R882C-IRES-EGFP, and 3 × 10
4
 GFP+ 
cells were transplanted with 2 × 10
5
 unfractionated competitor BM cells from congenic 
mice. For assessing the repopulating capacity on Bmi1 heterozygosity, c-kit+ Bmi1
+/+
 or 
Bmi1
+/-
 mouse BM cells were transduced with same vectors, and 2 × 10
5
 GFP+ cells 
were transplanted with the same number of unfractionated competitor BM cells from 
congenic mice. For second BMT assays, c-kit+ BM cells were obtained from recipient 
mice transplanted the cells transduced with pGCDNsam-IRES-KuOr, 
pGCDNsam-DNMT3A WT-IRES- KuOr, or pGCDNsam-DNMT3A R882H-IRES- 
KuOr four weeks after transplantation. Then, these cells were transduced with pMYs-IG 
or pMYs-PU.1-IG, and 2 × 10
5
 GFP and KuOr double positive cells were transplanted 
with 1 × 10
5
 unfractionated competitor BM cells from congenic mice to lethally 
irradiated mice. 
 
Flow Cytometry and Cell Cycle Analysis 
A list of antibodies is provided in Table 1. Stained cells were sorted with a 
FACSAriaII (BD), and analysis was performed on LSRII (BD). A mixture of antibodies 
recognizing CD3, CD4, CD8, B220, CD127, TER-119, Mac-1, or Gr-1 was used to 
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identify Lin+ cells. The data analyses were performed with FlowJo software (Tree Star). 
For the cell cycle analysis, after LSK staining, bone marrow cells were fixed and 
permeabilized using BD Cytofix/Cytoperm Fixation/Permeabilization Solution Kit (BD 
Biosciences) according to the manufacturer's recommendations. Subsequently, I stained 
with DAPI (Molecular Probes) and PE Ki-67 (BD Biosciences). 
 
Real-Time Quantitative PCR (qPCR) 
Real-time quantitative PCR was carried out on the LightCycler480 system (Roche) 
using SYBR Green reagents according to the manufacturer’s instructions.  The results 
were normalized to 18s rRNA levels. Relative expression levels were calculated using 
the 2-CT method. A list of primers is provided in Table 2. 
 
Targeted Bisulfite Sequencing 
Genomic DNA samples were extracted from GFP+LSK cells of transplanted mice 
and were subjected to bisulfite conversion with the EpiTect bisulfite kit (Qiagen) 
according to the manufacturer's instructions. Bisulfite-treated DNA was amplified with 
by PCR using gene-specific primers. PCR products were cloned into the pTAC2 vector 
(BioDynamics Laboratory), transformed into competent bacteria and sequenced. 
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Visualization of bisulfite sequence data for CpG methylation was performed using the 
QUMA web-based tool
35
. Sequences for the primers used in this study are provided in 
Table 2. 
 
Lentivirus Production and Transduction of AML Cell Lines 
To obtain lentivirus supernatants, HEK293T cells were transiently transfected with 
lentiviral vectors, MD2G packaging plasmid (Invitrogen), and PAX2 envelope plasmid 
(Invitrogen). The viral supernatant was collected 48 h after transfection and filtered to 
remove cellular debris. AML cell lines were infected with lentivirus in the presence of 
RetroNectin (Takara Bio Inc.). The infected cells were harvested 72 h after retrovirus 
infection, and vector-transduced cells were sorted and subjected to in vitro culture. 
When we used CSIV-TRE-RfA-UbC-KT doxycycline-inducible lentiviral vector, 1 
g/mL DOX was added to induce transgene expression. 
 
siRNA Interference 
Specific shRNAs targeting human RING1B mRNAs were designed and cloned 
into pSIREN-RetroQ-ZsGreen vector. Control shRNA is a nonfunctional construct 
provided from Clontech. The target sequences, from 5’ to 3’, were 
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GGAACTCAACCATTAAGCA (shRING1B #1), GGACTGCAATTATTCAGTA 
(shRING1B #2). To obtain amphotropic retrovirus supernatants, Plat-A packaging cells 
were transiently transfected with these constructs. Cultured cells were infected with 
amphotropic retrovirus in the presence of RetroNectin (Takara Bio Inc.). The infected 
cells were harvested 72 h after amphotropic retrovirus infection, and vector-transduced 
cells were sorted and subjected to in vitro culture. 
 
Assessment of Total CpG Methylation 
Total DNA methylation was measured as previously described
36
. In brief, 1 × 10
5
 
cells were washed with PBS, and fixed and permeabilized using BD Cytofix/Cytoperm 
Fixation/Permeabilization Solution Kit (BD Biosciences) according to the 
manufacturer's recommendations. Cells were incubated with anti-5-methylcytosine 
antibody (Calbiochem, NA 81) at 1:100 dilution for 30 min at room temperature. After 
washing with PBS, cells were incubated with secondary antibody coupled with Alexa 
Fluor 700 (Invitrogen) for 30 min in a dark-room environment. 
 
Immunoprecipitation and Western Blotting 
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Cell lysates were incubated with each antibody for 2 h at 4°C. Then, the samples 
were incubated with protein G–Sepharose (Amersham) for 1 h at 4°C. The precipitates 
were washed twice with the TNE buffer, twice with high salt-containing wash buffer 
(50 mM Tris-HCL [pH7.5], 500 mM NaCl, 0.1% Nonidet P40 (NP-40), 0.05% sodium 
deoxycholate), and once with low salt containing buffer (50 mM Tris-HCL [pH7.5], 
0.1% NP-40, 0.05% sodium deoxycholate) for epitope-tagged proteins, or washed five 
times with the TNF buffer for endogenous proteins. Then, the precipitates were 
analyzed by Western blotting. Blots were detected using an ImmunoStar Zeta (Wako 
Pure Chemical Industries) and an LAS-3000 image analyzer (Fujifilm) as recommended 
by the manufacturers. Immunoprecipitation and western blotting were performed using 
anti–Flag (Sigma-Aldrich), anti-Myc (Cell Signaling), anti-DNMT3A (Santa Cruz), 
anti-BMI1 (Millipore), anti-MEL18 (Santa Cruz), anti-RING1B (Cell Signaling), 
anti-RYBP (Millipore), anti-CBX7 (Abcam), and anti--actin (Cell Signaling) 
antibodies. 
 
Colony-Forming Assays and Cell Proliferation Analysis 
In each experiment, cells were plated into Methocult3434 (StemCell Technologies) 
medium. Colony numbers of each dish were scored on day 7. The number of cells 
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seeded into the plate was described in each figure legend. HOXA9-transduced 
immortalized cells after fourth round were then transferred into liquid cultute 
(RPMI1640 with 10% FCS, 10% conditioned medium from the WEHI-3B cell line, and 
1% PS at 37°C in a 5% CO2 incubator for cell proliferation analysis.Immortalized cells 
were cytospun and stained with Wright-Giemsa. 
 
ChIP and Quantitative PCR 
Cells were crosslinked with 1% of formaldehyde at room temperature for 15 min, 
and the reaction was stopped by the addition of glycine (2.5 M). Cells were rinsed three 
times with cold PBS, resuspended in lysis buffer 1 (50 mM HEPES-KOH [pH 7.5], 140 
mM NaCl, 1 mM EDTA, 10% Glycerol, 0.5% NP-40, 0.25% Triton, Roche protease 
inhibitor cocktail (Roche), and 1 mM PMSF) and rocked at 4°C on platform rocker for 
10 min. After centrifugation, each pellet was resuspended in lysis buffer 2 (10 mM 
Tris-HCl [pH 8.0], 200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, Roche protease 
inhibitor cocktail (Roche), and 1 mM PMSF) and rocked at room temperature for 10 
min. After centrifugation, each pellet was resuspended in lysis buffer 3 (10 mM 
Tris-HCl [pH 8.0], 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.1% 
sodium-deoxycholate, 0.5% N-lauroylsarcosine, Roche protease inhibitor cocktail 
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[Roche], and 1 mM PMSF) and sonicated with a ultrasonication (Covaris). Lysates were 
diluted with buffer 3 containing 1% TRITON X-100. When I utilized MNase, cell pellet 
was resuspended in MNase buffer (10 mM NaCl, 50 mM Tris [pH 7.5], 2.5 mM MgCl2, 
0.1% NP-40, 1mM DTT, EDTA free protease inhibitor cocktail, 10 mM CaCl2), and 
subjected to MNase digestion with 10000 U/mL (New England Biolabs). The digestion 
was stopped by adding EDTA and diluted with buffer-L (20 mM Tris-HCl [pH 7.5], 
150 mM NaCl, 0.5 mM EGTA, 1% Triton X-100, 0.1% sodium-deoxycholate, 0.1% 
SDS, and protease inhibitor cocktail), followed by ultrasonication. Then, 40 L of 
Dynabeads Protein G (Invitrogen) preloaded with 2 g of each antibody were added to 
the lysates for 2 h and then stringently washed for 5 times with wash buffer (50mM 
HEPES-KOH [pH7.5], 500 mM LiCl, 1 mM EDTA, 1% NP-40, and 0.7% sodium 
deoxycholate). Bound DNA fragments were eluted and quantified by subsequent 
real-time PCR. The antibodies used in ChIP assays were as follows: anti-Flag 
(Sigma-Aldorich), anti-DNMT3A (Abcam), anti-BMI1 (Millipore), anti-RING1B (Cell 
Signaling), anti-uH2A (Cell Signaling). A list of primers is provided in Table 2. 
 
Statistical Analysis 
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Statistical significance of differences between different groups was assessed with a 
2-tailed unpaired t test.  Differences were considered statistically significant at a p 
value of less than 0.05. 
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Results 
DNMT3A R882 mutation endows human AML cell lines with resistance to 
ATRA-induced neutrophil differentiation. 
I first investigated whether DNMT3A WT and R882 mutant could affect 
proliferation of human AML cell lines. I lentivirally transduced empty vector (EV), WT, 
or R882H to HL-60 and KG-1 cell lines which did not carry DNMT3A mutation
37
. 
DNMT3A WT-transduced AML cell lines resulted in decreased proliferation relative to 
EV and R882H-transduced cells (Figure 1). 
 
 
Figure 1. Growth curve of HL-60 (Left) and KG-1 (Right) cells transduced with EV, DNMT3A 
WT, or DNMT3A R882H. (N = 3 replicate experiments) Data are mean±SD values. *p<0.05 
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Subsequently, I evaluated the morphology of these transduced cells. DNMT3A 
WT-transduced HL-60 cells had some features of mature myeloid cells, such as small 
cell size, reduced nucleus-to-cytoplasm ratio, and segmented nucleus, whereas 
DNMT3A mutant-transduced cells remained immature morphology (Figure 2). 
 
Figure 2. Typical morphology of HL-60 cells transduced with EV, DNMT3A WT, or DNMT3A 
R882H. 
 
Next I quantified the levels of CD11b (Mac-1), a marker of myeloid lineage, of 
these cells five days and 10 days after transduction by flow cytometry. HL-60 cells did 
not express CD11b under normal condition and induction of differentiation by ATRA 
induced CD11b expression. CD11b positive rate was increased by more than 10-fold in 
DNMT3A WT-transduced cells compared to EV and R882H-transuduced cells (Figure 
3A and 3B). These morphologic and surface marker analyses demonstrated that 
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DNMT3A WT promote differentiation of AML cell lines whereas R882H mutant is 
defective in induction of differentiation. 
 
Figure 3. (A) Representative surface marker CD11b expression analyzed by flow cytometry of 
HL-60 cells transduced with EV, DNMT3A WT, or DNMT3A R882H. The boxed region shows 
CD11b positive rate at 10 days after transduction with EV, DNMT3A WT, or DNMT3A R882H. 
(B) Cumulative data of CD11b positive rate at five and 10 days after transduction with EV, 
DNMT3A WT, or DNMT3A R882H in HL-60. (N = 3 replicate experiments) Data are mean±
SD values. *p<0.05 
 
Additionally, there showed a marked difference in differentiation capacity induced 
by ATRA between DNMT3A WT-transduced HL-60 cells and R882H-transduced 
HL-60 cells (Figure 4A and 4B).  
 
 
 
 
A B 
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Figure 4. (A) Representative surface marker CD11b expression analyzed by flow cytometry of 
HL-60 cells transduced with EV, DNMT3A WT, or DNMT3A R882H. The boxed region shows 
CD11b positive rate at 48 h after transduction and administration of ATRA (1M). (B) 
Cumulative data of CD11b positive rate 24, 48, and 72 h after transduction with each vectors 
and administration of ATRA (1M). (N = 3 replicate experiments) Data are mean±SD values. 
*p<0.05, **p<0.01, ***p<0.001 
 
Taken together, these results indicate that DNMT3A WT induces terminal myeloid 
differentiation and inhibits proliferation of human AML cell lines, whereas R882 
mutant produces resistance to ATRA-induced neutrophil differentiation. 
 
 
 
 
A B 
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DNMT3A R882 mutation causes hematopoietic stem cell accumulation. 
I next investigated the effects of exogenous expression of DNMT3A R882 mutant 
protein in hematopoiesis by transducing 5-FU-primed mouse bone marrow cells with 
retroviral EV-, DNMT3A WT-, R882H-, or R882C-IRES-EGFP. GFP+ cells were 
sorted, then plated in methylcellulose to evaluate the colony-forming capacity in vitro 
and transplanted to lethally irradiated mice for assessing the repopulating capacity in 
vivo (Figure 5). 
 
Figure 5. Design of colony-forming assay and competitive repopulating assay with EV-, 
DNMT3A WT-, or DNMT3A R882 mutant-transduced 5-FU-primed murine BM cells. 
 
DNMT3A mutant-transduced cells generated comparable hematopoietic colonies 
to those of EV-transduced cells, while DNMT3A WT-transduced cells had a reduced 
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colony-forming capacity on the first round. All four types of cells could be replated up 
to the fourth round, which showed no sign of immortalization in vitro (Figure 6). 
 
 
Figure 6. Cumulative colony-forming capacity of each 1000 transgene-expressing cells at the 
initial plating is shown. (N = 5 replicate plates). Data are mean±SD values. *p<0.05, **p<0.01 
 
In murine BMT experiments, recipients transplanted with WT-transduced cells 
consistently exhibited lower chimerism in peripheral blood (PB) from four weeks after 
transplantation compared to EV control mice. On the other hand, recipients transplanted 
with R882 mutant-transduced cells showed comparable PB chimerism to EV-control 
(Figure 7A). Moreover, DNMT3A R882 mutant-transduced HSCs retained multilineage 
differentiation capacity up to 16 weeks after BMT compared to DNMT3A 
WT-transduced HSCs (Figure 7B). 
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Figure 7. (A) Contribution of EV, WT, R882H, and R882C to PB chimerism in primary 
competitive transplants, measured every four weeks. (N = 5-6 mice). (B) PB lineage distribution 
of the mice transplanted with EV-, WT-, or R882 mutant-transduced cells. Shown are 
percentage of donor-derived (GFP+) myeloid cells, B cells, and T cells, measured every four 
weeks. (N = 5-6 mice). Data are mean±SD values. *p<0.05 
 
These mice transplanted with R882 mutant-transduced cells did not exhibit any 
signs of leukemia for one-year observation (Figure 8), suggesting that retroviral 
overexpression of DNMT3A R882 mutant alone is insufficient to induce leukemic 
transformation in vitro and in vivo. 
 
 
 
 
A B 
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Figure 8. The plots of white blood cell count (Top), hemoglobin levels (Middle), and platelet 
count (Bottom) in PB up to one year after transplantation (N = 9 mice). Data are mean values. 
 
Because DNMT3A R882 mutant-overexpressed cells showed a superior 
engraftment to DNMT3A WT-overexpressed cells in PB of transplants, I sacrificed 
these transplanted mice at four weeks post-transplant and investigated whether 
exogenous expression of DNMT3A WT and R882 had altered BM stem/progenitor 
frequencies. Interestingly, while frequency of long-term HSC (LT-HSC; lineage- (L), 
Sca1+ (S), c-kit+ (K), CD150+, CD48-) was decreased in recipients of DNMT3A 
WT-transduced cells, R882 mutant caused an increase in LT-HSC frequency compared 
to EV-control recipients (Figure 9A and 9B). 
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Figure 9. (A) Representative flow cytometry data of BM cells from transplanted mice. The left 
boxed regions show the frequency of GFP+LSK cells in GFP+ cells. The right boxed region 
shows the frequency of GFP+CD150+CD48-LSK cells in GFP+ cells. (B) Cumulative data of 
the frequency of GFP+LSK cells in GFP+ cells (Upper) and GFP+SLAM LSK cells in GFP+ 
cells (Lower). (N = 5-6 mice). Data are mean±SD values. *p<0.05, **p<0.01 
 
B A 
 29 
 
Cell cycle analysis revealed that the percentage of cells in DAPI-Ki67- (G0 status; 
quiescent) was higher and the percentage of Ki67+ (proliferating) cells was lower in 
DNMT3A R882 mutant-transduced LSK cells compared to EV- and DNMT3A 
WT-transduced cells (Figure 10A and Figure 10B). 
 
Figure 10. (A) Representative flow cytometry data of cell cycle analysis. Murine BM cells were 
harvested from transplanted mice four weeks post-transplant and were gated first by GFP+LSK. 
The left lower boxed region shows the percentage of cells in G0 status in GFP+LSK cells. (B) 
Dot plots of the percentage of cells in G0 status (Left) and the percentage of Ki67 positive cells 
(Right). (N = 3 mice). Data are mean±SD values. *p<0.05, **p<0.01 
A 
B 
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These results demonstrate that exogenous expression of DNMT3A R882 mutation 
contributes to accumulation of quiescent HSCs, while overexpression of DNMT3A WT 
reduces frequency and functional repopulating capacity of HSCs. 
 
DNMT3A R882 mutation results in up-regulation of Hoxb cluster and 
down-regulation of differentiation-associated genes. 
To clarify down-stream target genes of mutant DNMT3A that evoked HSC 
accumulation, I sorted GFP+LSK cells from transplanted mice at four weeks 
post-transplant and conducted quantitative PCR experiment of various 
hematopoiesis-related genes which were deregulated in clinical AML samples harboring 
DNMT3A mutations and in Dnmt3a conditional knockout mice study described 
previously
14
. DNMT3A R882 mutant-transduced LSK cells showed higher Hoxb2 and 
Hoxb4 expression, both of which are known to be highly expressed in clinical AML 
samples harboring DNMT3A mutation
8
. On the other hand, Hoxa9 expression which is 
also highly expressed in clinical AML samples was not altered (Figure 11). Conversely, 
myeloid differentiation-associated genes, including PU.1 and Cebp, were 
down-regulated in DNMT3A mutant-transduced LSK cells. Other genes such as Nr4a2, 
a HSC fingerprint, Runx1 and Foxo1, both known to be essential for HSC function, 
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were up-regulated but not significantly in DNMT3A R882 mutant-transduced 
stem/progenitor cells. The trends of these gene expressions in DNMT3A R882 
mutant-transduced stem/progenitor cells were similar to those of Dnmt3a-null HSCs as 
described previously
14
  (Figure 11). 
 
Figure 11. Relative expression levels of various hematopoiesis-associated genes in GFP+LSK 
cells measured by qPCR. (N = 3 replicate experiments, normalized to the expression levels in 
EV-transduced LSK cells.) Data are mean±SD values. *p<0.05, **p<0.01, ***p<0.001 
 
Up-regulation of HSC self-renewal-associated genes and down-regulation of HSC 
differentiation-associated genes in DNMT3A R882 mutant-transduced stem/progenitor 
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cells highlight the phenotype of BMT experiments described above. Given that 
DNMT3A is a methyltransferase and R882 is located in the catalytic domain of 
DNMT3A, I subsequently analyzed DNA methylation status in vector-transduced 
stem/progenitor cells to elucidate whether the deregulated gene expression was due to 
altered DNA methylation status. Intracellular flow cytometry analysis revealed no 
significant difference in global 5-methylcytosine levels among four types of GFP+LK 
cells (Figure 12). 
 
Figure 12. Representative flow cytometry histograms of total CpG methylation of GFP+LK 
cells using 5-methylcytosine-specific antibody (Left). Quantification of total CpG methylation 
status shown as normalized mean fluorescence intensity (Right). (N = 3 replicate experiments) 
 
However, targeted bisulfite sequencing experiment using GFP+LSK cells showed 
hyper-methylation of the Hoxb2 promoter-associated CpG island in WT-transduced 
cells and hypo-methylation in R882H-transduced cells relative to EV-transduced control 
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cells (Figure 13). This altered CpG island methylation status was consistent with Hoxb2 
mRNA expression of transplanted mice. On the other hand, the decreased mRNA 
expression of PU.1 in DNMT3A mutant-transduced LSK cells was not associated with 
CpG methylation status. DNMT3A R882H evoked no change in methylation status of 
PU.1 promoter-associated CpG island. (Figure 13). 
 
 
Figure 13. Bisulfite sequencing analysis of promoter-associated CpG island of Hoxb2 (Left) and 
PU.1 (Right) in GFP+LSK cells. Arrows represent transcription start sites. Open and filled 
circles represent unmethylated and methylated CpGs, respectively. Data are mean±SD values. 
*p<0.05, **p<0.01, ***p<0.001 
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These results from the selected genes’ analysis indicate that DNMT3A R882 
mutants have DNA methylation-independent mechanism that causes down-regulation of 
differentiation-associated genes in addition to DNA methylation-dependent effect that 
leads to CpG hypo-methylation, followed by up-regulation of HSC 
self-renewal-associated genes as shown in the previous Dnmt3a knockout mice study. 
 
DNMT3A R882 mutation specifically interacts with Polycomb repressive 
complex 1. 
As noted above, DNMT3A interacts with several histone modifiers to repress the 
target gene expression. Especially, previous reports showed that the recruitment of 
PRC1 complex is affected by DNMT1, a member of DNA methyltransferases
38
, 
whereas most histone modifiers appear to be upstream landmarks of DNMT3A to 
catalyze DNA methylation
25,29
. Based on these facts, I hypothesized that the DNMT3A 
R882 mutants could alter the recruitment of collaborators to target gene loci, and I 
performed co-immunoprecipitation experiments using lysates from transiently 
transfected HEK 293T cells with expression vectors for DNMT3A WT or R882 mutants 
and several PRC1 components to elucidate the molecular mechanisms other than DNA 
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methylation. As with the analysis of transplanted mice, intracellular flow cytometry 
showed no difference in global 5-methylcytosine levels among four types of vector (EV, 
WT, R882H, R882C)-transfected HEK293T cells (Figure 14). 
 
Figure 14. Representative flow cytometry histograms of total CpG methylation of HEK293T 
cells transfected with each vector using 5-methylcytosine-specific antibody. 
 
Co-immunoprecipitation experiments showed that DNMT3A R882 mutant proteins 
had a greater affinity for BMI1 and RING1B, both of which are components of PRC1 
complex, than DNMT3A WT protein (Figure 15A and 15B). 
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Figure 15. Extracts from HEK293T cells co-transfected with FLAG-BMI1 (A) or -RING1B (B), 
and Myc-DNMT3A WT or –R882 mutants are immunoprecipitated with anti-FLAG antibody 
and are immunoblotted with either anti-FLAG or anti-Myc antibody. 
 
To further characterize the interaction between DNMT3A mutants and PRC1 
complexes, I transiently transfected HEK293T cells with FLAG-tagged DNMT3A WT 
or R882 mutant alone and pulled down by antibody against several PRC1 components 
and anti-FLAG antibody. Interestingly, DNMT3A R882H and R882C mutant proteins 
exhibited augmented interaction with BMI1 and MEL18 (Figure 16A and 16B). 
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Figure 16. Extracts from HEK293T cells transfected with FLAG-DNMT3A WT or –R882 
mutants are immunoprecipitated with anti-BMI1 (A) and MEL18 (B) antibody and are 
immunoblotted with anti-FLAG antibody. 
 
BMI1 and MEL18 are structural homologues that belong to different PRC1 
complexes, and both complexes maintain repression of gene expression by altering the 
chromatin status at specific promoters. Furthermore, RING1B, which is an essential 
common component of PRC1 complexes, was more firmly bound to DNMT3A R882 
mutant than DNMT3A WT, irrespective of the type of amino acid substitution (Figure 
17). These observations suggested that PRC1 complex favors DNMT3A R882 mutants 
over DNMT3A WT as a collaborating partner. 
 
 
 
A B 
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Figure 17. Extracts from HEK293T cells transfected with FLAG-DNMT3A WT or -R882 
mutants are immunoprecipitated with anti-RING1B and FLAG antibody and are immunoblotted 
with anti-FLAG and RING1B antibody, respectively. 
 
Previous reports have revealed that PRC1 complexes are divisible into two distinct 
types
39,40
, one is PRC2-dependent PRC1 complex (PDPC) and another is 
PRC2-independent PRC1 complex (PIPC). CBX proteins recognize histone H3K27me3 
and bind to these loci. Subsequently, PDPC represses the targeted gene expression 
through chromatin compaction and the placement of a repressive mark, histone 
H2AK119 ubiquitination. Therefore, to elucidate which PRC1 complex has enhanced 
interaction with DNMT3A R882 mutant, I pulled down the same sample with antibody 
against CBX7, a component of PDPC, and RYBP, a component of PIPC. Western 
blotting analysis revealed that DNMT3A R882 mutant (especially in R882H) had a 
greater affinity with CBX7 than DNMT3A WT (Figure 18A). On the other hand, no 
altered interaction between RYBP and DNMT3A R882 mutant was detected when 
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compared to DNMT3A WT (Figure 18B). These experiments characterized PDPC as a 
coordinating factor of DNMT3A R882 mutant. 
 
Figure 18. Extracts from HEK293T cells transfected with FLAG-DNMT3A WT or –R882 
mutants are immunoprecipitated with anti-CBX7 (A) and RYBP (B) antibody and are 
immunoblotted with anti-FLAG antibody. 
 
Finally, immunoprecipitation study revealed that an association between 
endogenous DNMT3A and MEL18 in OCI-AML3, a human AML cell line with 
DNMT3A R882C mutation (Figure 19)
 41
, which might emphasize the interaction 
between DNMT3A R882C and MEL18 in AML pathogenesis. 
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Figure 19. Endogenous interactions between DNMT3A R882C and MEL18. Extract from 
OCI-AML3 cells is immunoprecipitated with anti-MEL18 antibody or normal IgG and 
immunoblotted with anti-MEL18 or DNMT3A antibody. 
 
Together, these results showed that DNMT3A R882 mutation had enhanced 
interaction with PDPC without altered global 5-methylcytosine levels. 
 
PRC1 complex is required for DNMT3A mutation-induced stem cell 
accumulation through down-regulation of differentiation-associated 
genes. 
To assess the importance of the PRC1 complex interaction in vivo in DNMT3A 
R882 mutant-induced aberrant HSC accumulation, I performed transplantation assay 
using Bmi1 hetero-KO (Bmi1
+/-
) and Bmi1 WT (Bmi1
+/+
) littermate control mice. 
Previous reports revealed that Bmi1-null HSCs lose their stem cell function critically, 
but heterozygosity has little effect on normal hematopoiesis
42,43
. I transplanted EV, WT, 
B 
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or R882H-transduced c-kit+ mouse BM cells to lethally irradiated mice and analyzed 
these mice at four weeks post-transplant. Strikingly, heterozygosity of Bmi1 canceled 
the effect of DNMT3A R882 mutation without influence on EV-transduced HSC 
(Figure 20A and 20B), indicating that normal expression level of Bmi1 is required for 
DNMT3A R882 mutant-induced HSC accumulation.  
 
 
Figure 20. (A) Representative flow cytometry data of BM cells obtained from mouse 
transplanted with Bmi1
+/+
 (Left) or Bmi1
+/-
 (Right) cells transduced with EV, DNMT3A WT, or 
DNMT3A R882H. The boxed region shows the frequency of GFP+SLAM LSK cells in GFP+ 
cells. (B) Cumulative data of the frequency of GFP+SLAM LSK cells in GFP+ cells. (N = 4 
mice). Data are mean±SD values. *p<0.05, **p<0.01 
A 
B 
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I also sorted GFP+LSK cells from these mice and performed qPCR to assess the 
expression of potent target genes described above. Hoxb cluster genes, especially 
Hoxb2, were up-regulated in R882H-transduced LSK cells, irrespective of Bmi1 
genotype. Interestingly, Bmi1 heterozygosity restored the expression levels of 
down-regulated myeloid differentiation-associated genes (especially in PU.1) to normal 
levels in R882 mutant-transduced cells (Figure 21). 
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Figure 21. Relative expression levels of various hematopoiesis-associated genes in GFP+KSL 
cells measured by qPCR. (N = 3 replicate experiments, normalized to the expression levels in 
EV-transduced LSK cells.) Data are mean±SD values. *p<0.05 
 
These findings suggested that the augmented interaction between DNMT3A R882 
mutant and PRC1 complex was responsible for R882 mutant-induced HSC 
accumulation in vivo through silencing of differentiation-associated genes. Therefore, I 
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performed secondary BMT assay using murine PU.1 expression vector. KuOr-labeled 
EV, WT, or R882H-transduced c-kit+ cells sorted from primary recipient mice were 
transduced with EV or PU.1 (detected by GFP fluorescent protein). Subsequently, I 
transplanted double-transduced (GFP+KuOr+) cells to lethally irradiated mice (Figure 
22).  
 
Figure 22. Design of competitive repopulating assay in secondary recipient mice transplanted 
with EV- or PU.1-transduced EV-, DNMT3A WT-, or DNMT3A R882H-transduced c-kit+ 
cells obtained from primary recipient mice. 
 
The assessment of PB chimerism at four weeks post-transplant in each recipient 
group revealed that DNMT3A R882H-transduced stem/progenitor cells had a slightly 
but significantly higher repopulating capacity compared to EV control, and exogenous 
PU.1 expression almost totally impaired the repopulating capacity of EV and 
R882H-transduced cells, suggesting the functional role of PU.1 in the altered 
hematopoiesis by DNMT3A R882H (Figure 23). 
 
 45 
 
 
Figure 23. Contribution of EV, and PU.1 to PB chimerism at four weeks after transplantation in 
secondary recipients. (N = 4 mice). Data are mean±SD values. *p<0.05, **p<0.01, ***p<0.001 
 
To confirm that PU.1 is a direct target of aberrant collaboration between DNMT3A 
R882 mutant and PRC1 complex, I performed chromatin immunoprecipitation 
(ChIP)-qPCR experiment using HL-60 cells transduced with doxycycline-inducible 
DNMT3A WT or R882H mutant (Figure 24). 
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Figure 24. Protein expression of HL-60 cells transduced with doxycycline-inducible 
FLAG-tagged DNMT3A WT or R882H with or without administration of doxycycline using 
anti-FLAG antibody. -actin was blotted as a loading control. 
 
Because it took only five days for myeloid differentiation of HL-60 cells by the 
transduction of DNMT3A WT (Figure 3), I utilized doxycycline-inducible vector and 
analyzed the undifferentiated HL-60 cells at day 3 post doxycycline induction. 
ChIP-qPCR experiment using crosslinked cells three days after doxycycline 
administration revealed that BMI1 and RING1B were more efficiently recruited to the 
upstream regulatory element (URE) of PU.1 upon expression of DNMT3A R882H than 
DNMT3A WT, while the amount of DNMT3A recruited were comparable between 
DNMT3A WT and R882H. In addition, RING1B-mediated ubiquitination of histone 
H2AK119 was more enriched at the same locus in DNMT3A R882H mutant-transduced 
HL-60 cells (Figure 25). 
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Figure 25. ChIP-qPCR experiment of the PRC1 components BMI1 and RING1B, DNMT3A, 
and ubiquitinated H2A in HL-60 cells at the URE, a 5kb upstream region, and proximal 
promoter region of PU.1 in the absence of or in the presence of either doxycycline-inducible 
DNMT3A WT or DNMT3A R882H. (N = 3 replicate experiments except for IgG control (N=1) 
and ubiquitinated H2A in DOX(-) (N=2)) Data are mean±SD values. *p<0.05 between WT 
DOX(+) and R882H DOX(+). 
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From these results, it is supposed that transcriptional silencing of PU.1 comes from 
increased URE occupancy of PRC1 complex upon expression of DNMT3A R882H. 
Furthermore, these data suggest that enhanced interaction between DNMT3A R882 
mutant and PRC1 complex decreases mRNA levels of myeloid 
differentiation-associated genes, which might play a positive role in the increased 
frequency of DNMT3A R882 mutant-transduced HSCs. 
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PRC1 complex is essential to development, maintenance, and ATRA 
resistance of DNMT3A mutant-associated leukemic cells. 
As revealed above, DNMT3A R882 mutant alone is insufficient to cause 
leukemic transformation in vitro and in vivo (Figure 6 and Figure 8). Therefore, I 
searched some potent collaborating genes for development of AML from public 
database, resulting the finding that HOXA and HOXB cluster genes were highly 
expressed in clinical AML samples harboring DNMT3A mutation
8,44
. From my mice 
study, Hoxb cluster genes were up-regulated in DNMT3A R882 mutant-transduced 
murine HSCs, but Hoxa cluster genes were not altered by DNMT3A mutant alone 
(Figure 11). As exogenous expression of HOXA9 induces immortalization in 
methylcellulose assay and myeloproliferative disease in vivo
45
, I co-transduced 
DNMT3A and HOXA9 to mouse BM c-kit+ cells and performed colony replating assay 
to assess whether DNMT3A mutation had an additional effect on HOXA9-induced 
myeloproliferative disease (Figure 26).  
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Figure 26. Design of CFU and liquid culture assay with HOXA9 and EV-, DNMT3A WT-, or 
DNMT3A R882 mutant-transduced c-kit sorted murine BM cells. 
 
In in vitro colony replating assay, DNMT3A WT and HOXA9 co-transduced cells 
had no colony formation at third replating whereas BM cells transduced with HOXA9 
plus EV or DNMT3A R882H could easily be replated multiple times (immortalized) 
and generated large colonies than DNMT3A WT and HOXA9 co-transduced cells (data 
not shown). After the fourth round of replating, immortalized cells were transferred to 
liquid culture containing IL-3. While HOXA9 and EV co-transduced cells showed a 
decline in cell growth from three days after the transfer, HOXA9 plus R882H 
transduced immortalized cells slowly but steadily proliferated for one week, indicating 
the proliferative advantage of DNMT3A R882H in concert with HOXA9 (Figure 27). 
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Figure 27. Growth curve of Bmi1
+/+
 and Bmi1
+/-
 murine immortalized cells transduced with 
HOXA9 and EV or DNMT3A R882H in liquid culture. (N = 3 replicate experiments) Data are 
mean±SD values. *p<0.05 
 
 Morphological and surface marker analysis of these immortalized cells revealed 
that the most of HOXA9 and EV co-transduced cells were mature granulocytes, 
monocytes and macrophages and that HOXA9 and DNMT3A R882H co-transduced 
cells were mainly F4/80+, Mac1+, Gr1- monocytic blasts, consistent with clinical 
observation that DNMT3A mutation is found frequently in FAB M4/M5 leukemia 
(Figure 28A and 28B). 
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Figure 28. (A) Typical morphology of Bmi1
+/+
 and Bmi1
+/-
 murine immortalized cells 
transduced with HOXA9 and EV or DNMT3A R882H in liquid culture. (B) Representative 
surface maker of Bmi1
+/+
 murine immortalized cells transduced with HOXA9 and DNMT3A 
R882H. 
 
 These results indicate a distinct role for DNMT3A mutation as well as a potential 
collaboration between DNMT3A R882H and HOXA9 in malignant transformation of 
hematopoietic cells. Subsequently, I assessed the impact of PRC1 complex on this 
monoblastic transformation using Bmi1
+/-
 and Bmi1
+/+
 littermate control mice. 
Although BM cells transduced with HOXA9 plus EV or DNMT3A R882H 
B 
A 
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immortalized, irrespective of Bmi1 genotype, Bmi1 heterozygosity reduced the colony 
number of HOXA9 and R882H co-transduced cells at the first round (Figure 29).  
 
Figure 29. Cumulative colony-forming capacity is shown for an initial plating of 1000 
co-transgene-expressing cells. (N = 3 replicate plates). Data are mean±SD values. *p<0.05 
 
Furthermore, Bmi1 heterozygosity impaired monoblastic transforming capacity 
and growth advantage of HOXA9 and R882H co-transduced progenitors. 
Wright-Giemsa staining showed that cells from HOXA9 and R882H co-transduced 
Bmi-1
+/-
 -derived third round colonies were fully composed of mature macrophages and 
granulocytes (Figure 27 and 28A). These results suggested that normal expression level 
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of Bmi1 is also indispensable for the differentiation block of DNMT3A R882H and 
HOXA9 co-transduced murine BM cells. 
 In order to investigate the importance of PRC1 complex for maintenance and 
ATRA-resistance of DNMT3A-mutated AML, I next designed two shRNAs targeting 
RING1B, and retrovirally transduced these vectors to OCI-AML3 (DNMT3A mutated) 
and THP1 (DNMT3A not mutated) cell lines, and HL-60 cells were transduced with 
doxycycline-inducible DNMT3A WT or R882H. Western blotting analysis of RING1B 
in HL-60 cells showed a 50-60% reduction of RING1B compared to the control shRNA 
vector-transduced HL-60 cells (Figure 30). 
 
Figure 30. Protein expression of HL-60 cells transduced with shControl, shRING1B-1, or 
shRING1B-2 using anti-RING1B antibody. -actin was blotted as a loading control. 
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 RING1B knockdown significantly showed a decreased proliferative capacity of 
OCI-AML3 cells (Figure 31A). Wright-Giemsa staining of these cells revealed that 
OCI-AML3 cells expressing RING1B shRNA were mature cells morphologically as 
typified by small cell size, reduced nucleus-to-cytoplasm ratio, and segmented nucleus 
(Figure 32). When the same setting of RING1B knockdown was applied to THP1 cells, 
a monocytic AML cell line not carrying DNMT3A mutation
46
, reduction in RING1B 
expression did not affect the proliferation rate and morphology in THP1 cells (Figure 
31B). These experiments suggested that RING1B plays an essential role for 
maintenance of DNMT3A-mutated monocytic AML cell line. 
 
 
Figure 31. Growth curve of OCI-AML3 (A) and THP1 cells (B) transduced with shControl or 
shRING1B. (N = 3 replicate experiments) Data are mean±SD values. *p<0.05 
 
A B 
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Figure 32. Typical morphology of OCI-AML3 and THP1 cells transduced with shControl or 
shRING1B-1. 
 
In experiments using HL-60 cells transduced with doxycycline-inducible 
DNMT3A WT or R882H, knockdown of RING1B eliminated the distinction between 
WT- and R882H-transduced cells in the growth curve and the difference between 
R882H-non expressed and R882H-expressed cells in the sensitivity to ATRA, although 
it was possible that RING1B could have its own effectors on the proliferative capacity 
and the expression of CD11b of HL-60 in DNMT3A mutant-independent manner 
(Figure 33A, 33B, and 33C). 
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Figure 33. (A) Growth curve of HL-60 cells transduced with doxycycline-inducible DNMT3A 
WT or DNMT3A R882H, and shControl or shRING1B. (N = 3 replicate experiments) (B) 
Cumulative data of CD11b positivity rate 48 h after doxycycline-induced transgene expression 
and administration of ATRA (1M) or EtOH. (N = 3 replicate experiments) (C) Representative 
surface maker CD11b expression of HL-60 cells transduced with doxycycline-inducible 
DNMT3A WT or R882H, and shControl or shRING1B at 48 h after doxycycline-induced 
transgene expression and administration of ATRA (1M) or EtOH. Data are mean±SD values. 
*p<0.05, **p<0.01 
 
A B 
C 
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In summary, these results demonstrate that PRC1 complex is necessary for 
monoblastic transformation of BM progenitors with DNMT3A R882 mutant and 
HOXA9 overexpression, for differentiation block, and for resistance to 
differentiation-inducing therapy of DNMT3A-mutated AML cells. 
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Discussion 
The data presented here identified that DNMT3A R882 mutation results in 
differentiation block of HSCs and leukemic cells, and promoting leukemic 
transformation in combination with HOXA9 via aberrant recruitment of PRC1 complex 
to specific differentiation-associated gene loci. 
DNMT3A mutation has been so far thought to be a loss-of-function mutation due to 
the reduced DNA methyltransferase activity of purified DNMT3A R882 mutant protein 
and the premature truncated protein translated from the remaining mutations
8
. Several 
evidence regarding DNMT3A mutant in AML as described below have prompted me to 
hypothesize that DNMT3A R882 mutation has certain gain-of-function and/or 
dominant-negative effects: (1) The most prevalence of R882 mutation up to 60% in 
DNMT3A-mutated AML; (2) Heterozygous DNMT3A R882 mutations as the most 
frequent genotype in AML; (3) No apparent phenotype in Dnmt3a hetero-knockout 
mice
47
. To test my hypothesis, I utilized viral overexpression system for the forced 
expression of DNMT3A mutations into primary murine cells and cell lines. In the 
system, DNMT3A mutants were successfully and functionally analyzed by comparing 
samples with forced expression of empty vector or DNMT3A WT, although there lied 
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some limitations regarding the system such as the relatively higher level of DNMT3A 
expression than human primary AML samples and the vector-derived insertional 
mutagenesis. In fact, I found that DNMT3A R882 mutant contributed to insensitivity to 
ATRA-induced differentiation of AML cell lines and promoted monoblastic 
transformation of normal stem/progenitor cells in combination with HOXA9, while EV 
and HOXA9 co-transduced cells did not transform. From my murine BMT assays, 
aberrant expression of DNMT3A R882 mutant alone was insufficient for leukemia 
development indicating that DNMT3A R882 mutant would require one or more 
additional genetic events to develop myeloid malignancies. Indeed, some recent studies 
revealed that DNMT3A mutations are identified as an early genetic event and 
remarkably stable during AML evolution
48-50
. Furthermore, somatic mutations of 
DNMT3A are shown to be detected in blood cells from healthy elderly individual and 
the donor cells of HSC transplantation
51,52
, consistent with our findings that 
accumulated HSCs evoked by DNMT3A R882 mutant are in a quiescent state. With the 
fact that DNMT3A-mutated hematological diseases comprise not only AML but also 
myelodysplastic syndrome, and T-cell leukemia/lymphoma, it is also suspected that the 
altered genetic and epigenetic mechanism in HSC by DNMT3A mutation would form 
the backbone of premalignant status of HSCs. As described above, patients harboring 
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DNMT3A mutations frequently have NPM1 mutations. The previous report showed that 
NPM1 mutant knock-in allele in mouse hematopoietic cells causes up-regulation of 
Hoxa9 in mice
53
. Because HOXA9 is overexpressed in DNMT3A-mutated AML 
samples, but not altered in DNMT3A mutant-transduced murine LSK cells, I selected 
HOXA9 as a potential collaborating oncogene. As a result, I found that DNMT3A R882 
mutant blocks myeloid differentiation and promote monoblastic transformation when 
combined with HOXA9. 
Based on my findings, I propose that DNMT3A R882 mutant has two distinct 
mechanisms for leukemogenesis: (1) DNA methylation-dependent effect, leading to 
DNA hypo-methylation; (2) DNA methylation-independent effect, recruiting the PRC1 
complex to specific target loci. Firstly, as an indicator of DNA methylation-dependent 
effect, exogenous expression of DNMT3A R882 mutant caused up-regulation of Hoxb2 
with accompanying hypo-methylation of the promoter-associated CpG island in murine 
stem/progenitor cells possibly due to the disruption of DNMT3A tetramerization 
capacity
13
, consistent with previous analysis using patient samples
8
. Secondary, as an 
indicator of DNA methylation-independent mechanism, my data indicated that 
DNMT3A R882 mutation-mediated recruitment of PRC1 complex to specific target loci 
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suppressed the expression of differentiation-associated genes, blocking differentiation 
of HSCs and leukemic cells (Figure 34). 
 
 
Figure 34. Schematic model of aberrant collaboration between DNMT3A R882 mutant and 
PRC1 complex in promoting differentiation block in HSCs and leukemic cells. Hoxb cluster 
genes, stem cell genes, and differentiation-associated genes are direct targets of DNMT3A. 
When HSCs or leukemic cells receive a differentiation signal, DNMT3A WT methylates these 
genes’ promoter-associated CpG island and suppresses their mRNA transcription, leading to 
hematopoietic differentiation to progenitors and mature blood cells (Upper left). DNMT3A 
R882 mutant not only is incapable of methylating these regions but also disrupt the normal 
function of remaining WT allele, leading to up-regulation of these target genes, especially 
Hoxb2 (Left lower). Furthermore, DNMT3A R882 mutant recruits PDPC to the regulatory 
region of differentiation-associated genes. PDPC recruited by DNMT3A R882 mutant silence 
these genes’ expression through the placement of a repressive mark, ubiquitinated H2AK119 
contributing to the development of pre-leukemic state (HSC accumulation), leukemic state 
(monoblastic transformation), and therapy resistance (insensitivity to ATRA) (Right). 
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Based on the fact that Hoxb4 is a well-known inducer of HSC self-renewal in 
mice
54
, it is possible that transcriptional activation of Hoxb cluster mediated by 
DNMT3A mutant causes expansion of stem cell fraction. However, considering the 
quiescent status of DNMT3A mutant-transduced HSCs with no proliferative advantage 
in colony formation, I additionally hypothesized that down-regulation of 
differentiation-associated genes was more important for the phenotypes described above. 
Indeed, I identified that DNMT3A R882 mutant-induced insensitivity to ATRA in 
HL-60 cells, aberrant HSC accumulation, and monoblastic transformation were 
abrogated by suppression of PRC1 complex as represented by Bmi1 heterozygosity and 
knockdown of RING1B. 
Many studies utilizing knockout mouse of several components of PRC1 subunit 
revealed that PRC1 complex plays a crucial role for HSC self-renewal and 
differentiation through ubiquitination of histone H2AK119 and chromatin compaction 
in the last decade
55,56
. Especially, Bmi1 is well known to be an important regulator of 
HSC and some kind of leukemia stem cell self-renewal. Bmi1-null HSCs lose their 
long-term repopulating capacity and cause postnatal pancytopenia and death within 2 
months after birth, while its heterozygosity has less impact on normal hematopoiesis
42,43
. 
On the other hand, Bmi1 deficiency reduces a clonogenic and proliferative capacity of 
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AML1-ETO, PLZF-RAR, and MLL-AF9 oncogenes causing immortalization of 
normal progenitors in vitro
57,58
. In addition, the previous study reported that 
heterozygosity of Bmi1 reduces E-myc transgene-induced lymphomagenesis in mice59. 
Similarly, I found that Bmi1 heterozygosity counteracted the accumulation of HSC 
frequency by DNMT3A R882 mutant but that Bmi1 heterozygosity had no apparent 
impact on HSC frequency in mice transplanted with EV-transduced cells. 
Overexpression of BMI1 is commonly found in several hematological malignancies and 
correlates with disease prognosis
60
, however, recurrent somatic mutations in PRC1 
components have not been reported
61
. Given these clinical evidences, endogenous or 
higher expression of PRC1 complex would be essential for development and 
maintenance of not only DNMT3A R882-mutated AML but also a wide range of 
hematological diseases. 
As described above, several recent reports have revealed that PRC1 complexes are 
classified into two distinct groups, PDPC and PIPC. The genome-wide localization of 
Cbx7 (representative for PDPC) and Rybp (representative for PIPC) showed that both 
complexes co-localize at many of the same loci, but also target the independent genes in 
mouse ESCs
62
. My immunoprecipitation analysis indicated that only PDPC was 
associated with DNMT3A R882 mutant-induced several phenotypes. In ESCs, PIPC 
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targets are enriched in germline regulator genes, whereas PDPC target are enriched in 
cell differentiation-, lineage commitment-, and developmental regulator-associated 
genes in line with my observation
62
, although further study concerning the functional 
role of each complexes including genome-wide occupancy analysis in hematopoietic 
cells is remained to be done. In fact, I found that DNMT3A R882 mutant-associated 
PRC1 complex had a higher affinity to the PU.1 URE region, indicating that 
PDPC-based transcription silencing mechanism in cell differentiation and lineage 
commitment could be applied to the hematopoietic system. PU.1 is one of the most 
essential transcription factors of hematopoietic lineage development, and is required for 
the maturation of common myeloid progenitor and granulocyte-monocyte progenitor
63
. 
Inactivating mutation of PU.1 is detected in 7% of AML patients, and enriched in FAB 
M4/M5 AML as with the case of DNMT3A mutation
64
. In addition, down-regulation of 
PU.1 is also associated with leukemogenesis of several important oncogenes, such as 
AML1-ETO, FLT3-ITD, MN1, and PML-RAR65-68. Especially, exogenous expression 
of MN1 suppresses PU.1 expression and inhibits its activation by ATRA, promoting 
resistance to ATRA-induced differentiation in hematopoietic cells, consistent with my 
findings
67
. Based on the result that MN1 expression levels predict ATRA-resistance in 
patients with AML
67
, it is important to verify the insensitivity to 
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differentiation-inducing therapy in DNMT3A-mutated AML cells using patient 
samples. 
In summary, my study has revealed that the mechanism of DNMT3A mutant to 
promote leukemogenesis via collaborating with PRC1 complex for transcriptional 
silencing of differentiation-associated genes. This accomplishment of the functional 
analysis of DNMT3A mutant by overexpression system could tie in the concept 
generating heterozygous DNMT3A R882 mutant knock-in mouse model to cover the 
precise biological and molecular mechanism of DNMT3A mutant and PRC1 complex. 
The knock-in mouse model would be expected to overcome some limitations of this 
study in that the model could validate whether the endogenous expression of mutated 
DNMT3A protein possesses the similar function to overexpressed DNMT3A mutant. It 
is also to be addressed in the future how PRC1 complex is recruited to DNMT3A 
mutant target genes. Even considered that BMI1 is essential for normal hematopoiesis, 
attenuating the functional cooperation between DNMT3A mutant and PRC1 complex 
could be a promising therapeutic target in DNMT3A-mutated hematological 
malignancies. 
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Tables 
Table 1. A list of antibodies for flow cytometry 
Epitope Clone Conjugate Dilution Company 
Gr-1 RB6-8C5 Biotin 1:200 Bioleged 
 
RB6-8C5 APC 1:200 Bioleged 
Mac-1 M1/70 Biotin 1:200 Bioleged 
 
M1/70 APC 1:200 Bioleged 
B220 RA3-6B2 Biotin 1:200 Bioleged 
 
RA3-6B2 PerCP 1:200 BD 
TER-119 TER-119 Biotin 1:200 Bioleged 
CD3 145-2C11 Biotin 1:200 Bioleged 
CD4 GK1.5 Biotin 1:200 Bioleged 
CD8a 53-6.7 Biotin 1:200 Bioleged 
CD127 A7R34 Biotin 1:200 Bioleged 
Sca-1 E13-161.7 PerCP-Cy5.5 1:200 Bioleged 
c-kit 2B8 APC 1:200 Bioleged 
 
2B8 PE-Cy7 1:200 BD 
CD48 HM48-1 PE 1:200 BD 
CD150 TC15-12F12.2 APC 1:200 Bioleged 
F4/80 BM8 APC 1:200 Bioleged 
CD11b (Human) ICRF44 APC 1:200 Bioleged 
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Table 2. A list of PCR primer sequences 
Gene Species Type Forward Reverse 
PU.1 Mouse BS sequencing TTAGAGGGGATTGAGAAGAAAT TCAAACCTACCCCCTAAACTAC 
Hoxb2 Mouse BS sequencing AGAGGAGGAAGTTTTATGGTATTTAG CAAATTCAAAATTCATAACTTTCAATA 
  
   
PU.1 (URE) Human ChIP-qPCR GCACACATGCTTCCTGTGGTGACT CCACGTGCCCTGACTCCCCTCCTAGC 
PU.1 (-5kb) Human ChIP-qPCR ATCTGTTCACATGGGCTTCC TGGTGGATAGGCAAGAAAGG 
PU.1 (Proximal) Human ChIP-qPCR CTGGTCAGCAGGAAATTGGT GGGAACTGGGCAGTTGTTTA 
  
   
Hoxa5 Mouse RT-PCR TATAGACGCACAAACGACCGC CATTTGGATAGCGACCGCA 
Hoxa9 Mouse RT-PCR GCGCCTTCTCCGAAAACA CCGGGTTATTGGGATCGAT 
Hoxb2 Mouse RT-PCR CCCGCTGTCTTGGAGACATTT TTTTGGCTCCCTGGTCTCTGA 
Hoxb4 Mouse RT-PCR TTCACTACAATCGCTACCTGACGC GGTGTTGGGCAACTTGTGGTCTTT 
Runx1 Mouse RT-PCR AACCCTCAGCCTCAAAGTCA GGGTGCACAGAAGAGGTGAT 
Nr4a2 Mouse RT-PCR CGCCGAAATCGTTGTCAGTA CGACCTCTCCGGCCTTTTA 
Foxo1 Mouse RT-PCR AAGAGGCTCACCCTGTCGC GCATCCACCAAGAACTTTTCC 
Meis1 Mouse RT-PCR CATGATAGACCAGTCCAACCGA ATTGGCTGTCCATCAGGGTTA 
Cebp Mouse RT-PCR AAACAACGCAACGTGGAGA GCGGTCATTGTCACTGGTC 
PU.1 Mouse RT-PCR CAGAAGGGCAACCGCAAGAA GCCGCTGAACTGGTAGGTGA 
Gata3 Mouse RT-PCR GGGTTCGGATGTAAGTCGAG CCACAGTGGGGTAGAGGTTG 
Pbx1 Mouse RT-PCR AGGACATCGGGGACATTTTAC CATTAAACAAGGCAGGCTTCA 
Evi1 Mouse RT-PCR GGAGGAGGACTTGCAACAAA GACAGCATGTGCTTCTCCAA 
Mef2c Mouse RT-PCR AGGTGTTGCTCAAGTACACCGAGT ATCTCAAAGCTGGGAGGTGGAACA 
PU.1 Human RT-PCR GGGAGAGCCATAGCGACCAT TAGGAGACCTGGTGGCCAAGA 
18s rRNA 
Human 
Mouse 
RT-PCR GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG 
 
 
